Dawei Bio Announces Close Of Series Pre-A Financing Round

(VCBeat) Mar. 27, 2021 -- Recently, Beijing Dawei Biotechnology Co., Ltd. ("Dawei Bio") announced the completion of the Series Pre-A round of financing, led by Qingkong SinoKing Capital, with participation from Maccura Biotechnology. Dawei Bio is committed to the development of medical devices for genetic testing and clinical applications. Proceeds from the latest round will be used for the R&D of a number of innovative molecular diagnostic reagents, the promotion of clinical trials, the construction of production lines and the registration of products at home and abroad.

On the basis of 20 years of R&D of microfluidic technology, Professor Du Wenbin, founder of Dawei Bio and the Institute of Microbiology, Chinese Academy of Sciences, has achieved an independent innovation breakthrough -- the DAPCO^® technology Droplet Array Production by Cross-interface Oscillation, interface vibration droplet array). The company has independent intellectual property rights of the OsciDrop^® series digital PCR instruments, supporting consumables, general reagents and other products, which takes the lead in China and the United States and broke the monopoly of foreign technology. Dawei Bio has launched a chipless integrated digital PCR instrument and related products and applications with huge potential in the domestic and international market.

Dawei Bio has made progress in tumor precision diagnosis, infectious disease detection, multiplex detection system for genetically modified (GM) food ingredients and other aspects, which has greatly expanded the scope of application and quantitative accuracy of molecular diagnosis.

During the epidemic, Dawei Bio actively participated in the calibration of nucleic acid reference materials of inactivated COVID-19 virus, which provided an important basis for the establishment of high-quality reference materials. At present, Dawei Bio's digital PCR instrument and the supporting reagents and consumables have entered the stage of stable mass production. The company has established extensive cooperation with dozens of domestic third-grade hospitals, testing institutions, biomedical enterprises, scientific research institutes and so on.

Qingkong SinoKing Capital is a professional institution among the member enterprises of Qingkong Asset Management Group under Tsinghua Holdings focused on industrial investment and asset management. The company is backed by the advantages of Tsinghua's resources in production, learning and research, adhering to the concept of " based in technology, applied to finance" to cultivate strategic emerging industries and financial capital markets.

Maccura was founded in 1994 and has been focusing on the research, manufacture, marketing, and services of IVD products. Its products have covered platforms of biochemistry, immunoassay, POCT, hematology, molecular diagnosis and pathology, and could meet more than 90% requirements of medical labs with the product integration.